Publications

Add filters (0)

386 results

Influence of food intake on the bioavailability and efficacy of oral calcitonin.

April 1, 2009

Br J Clin Pharmacol

Abstract AIMS To investigate the influence of food intake on the bioavailability and pharmacodynamic effects of salmon calcitonin (sCT). METHODS A single-blind, randomized, partly placebo-controlled study was conducted in 36 healthy postmenopausal female volunteers aged 62-74 years. The influence of food intake on oral dosing with 0.8 mg of sCT at 22.00 h was evaluated […]

Read publication

Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI.

March 1, 2009

Osteoarthritis Cartilage

Abstract OBJECTIVE Osteoarthritis (OA) is characterized by increased bone and cartilage metabolism leading to joint damage. The urinary excretion of C-telopeptides of type II collagen (CTX-II) has earlier predicted progression in radiographic OA (ROA)–useful for participant selection in clinical studies of potential disease modifying OA drugs (DMOADs). We investigated the longitudinal interrelationship between CTX-II and […]

Read publication

A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin.

February 1, 2009

J Clin Pharmacol

Abstract The aim of this study was to assess the bioavailability and pharmacodynamic efficacy of synthetic salmon calcitonin (ssCT) and recombinant salmon calcitonin (rsCT) in healthy postmenopausal women. The study was a single-blind, randomized study. Participants were 36 postmenopausal women 62 to 74 years old, randomly assigned to a comparison of dosing with ssCT (n […]

Read publication

Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers.

January 1, 2009

Arthritis Res Ther

Abstract INTRODUCTION At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations of biochemical and magnetic resonance imaging (MRI)-based markers provided effective diagnostic and prognostic tools for […]

Read publication

Oestrogen exhibits type II collagen protective effects and attenuates collagen-induced arthritis in rats.

April 1, 2008

Clin Exp Immunol

Abstract As anti-inflammatory treatments used in rheumatoid arthritis, such as glucocorticoids, often result in secondary detrimental effects on bone health, the objective of this study was to investigate the effects of oestrogen therapy (ET) on the development and activity of collagen-induced arthritis (CIA) in rats, with a focus on assessment of chondroprotective effects using biomarkers […]

Read publication

Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases.

May 1, 2007

Osteoporos Int

Abstract Numerous experimental and clinical observations suggest that overall changes in bone resorption during menopause or treatment with hormone replacement therapy (HRT) are combined effects of changes in osteoclast number and function. Moreover, due to a coupling between osteoclastic bone resorption and osteoblastic bone formation, pronounced alteration of osteoclast number will eventually lead to alteration […]

Read publication

Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen.

March 1, 2007

Osteoarthritis Cartilage

Abstract OBJECTIVE The aim of the present study was to investigate collagen metabolism after anabolic and catabolic stimulation of chondrocytes ex vivo. DESIGN Metabolic activities in ex vivo bovine cartilage explants were stimulated with insulin-like growth factor I (IGF-I) or a combination of tumor necrosis factor alpha (TNFalpha) and oncostatin M (OSM). Supernatants were assessed […]

Read publication

Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review.

December 1, 2006

Biomarkers

Abstract Emerging evidence supports the concept that biochemical markers are clinically useful non-invasive diagnostic tools for the monitoring of changes in cartilage turnover in patients with destructive joint diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA). Epidemiological studies demonstrated that measurements of different degradation products of proteins in the extracellular matrix of hyaline cartilage […]

Read publication

An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice.

October 1, 2006

Eur J Clin Pharmacol

Abstract BACKGROUND Maintenance of the structural and functional integrity of the skeleton is a critical function of a continuous remodeling driven by highly associated processes of bone resorption and synthetic activities driven by osteoclasts and osteoblasts, respectively. Acceleration of bone turnover, accompanied with a disruption of the coupling between these cellular activities, plays an established […]

Read publication

Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes.

August 1, 2006

Osteoarthritis Cartilage

Abstract OBJECTIVE Calcitonin was recently reported to counter progression of cartilage degradation in an experimental model of osteoarthritis, and the effects were primarily suggested to be mediated by inhibition of subchondral bone resorption. We investigated direct effects of calcitonin on chondrocytes by assessing expression of the receptor and pharmacological effects on collagen type II degradation […]

Read publication